MACULAR DEGENERATION TREATMENT MARKET ANALYSIS

Macular Degeneration Treatment Market, By Type (Dry Age-related Macular Degeneration and Wet Age-related Macular Degeneration), By Stage Of Disease (Early-stage AMD, Intermediate AMD, and Late-stage AMD), By Route Of Administration (Intravenous Route and Intravitreal Route), By Sales Channel (Ambulatory Surgical Centres, Hospitals, and Other Sales Channels), and By Geography (North America Europe, Asia-Pacific, South America, and Middle East & Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Aug 2022
Code : CMI5149
Pages :174
Formats :
Excel and PDF
Industry : Pharmaceutical

Macular Degeneration Treatment MarketSize and Trends

Market Statistics:

The global macular degeneration treatment market was valued at US$ 8,208.7 Mn in 2021 and is forecast to reach a value of US$ 13,195.7 Mn by 2028 at a CAGR of 7.0% between 2022 and 2028.

North America held dominant position in the global macular degeneration treatment market in 2020, accounting for 38.5% share in terms of volume, followed by Europe and Asia Pacific, respectively.

Figure 1. Global Macular Degeneration Treatment Market Share (%), by Region, 2021

Market Trends/Key Takeaways:

Frequent approvals and launches of novel products is expected to drive growth of the global macular degeneration treatment market. For instance, in October 2021, Roche announced that the Food and Drug Administration (FDA) has approved Susvimo (100 mg/mL ranibizumab injection) for the treatment of wet, or neovascular, age-related macular degeneration (AMD), a condition that can lead to rapid and severe loss of vision.
Introduction of novel products by market players is expected to augment the growth of the global macular degeneration treatment market. For instance, in September 2019, Boehringer Ingelheim and Inflammasome Therapeutics Inc. signed an agreement to develop three therapies for patients suffering with retinal diseases such as age-related macular degeneration (AMD), diabetic macular edema (DME), and diabetic retinopathy (DR).